Endocrine Abstracts

Background: Osteocalcin, a marker of bone formation, is also known as a regulator of glucose and fat mass. The purpose of this study was to determine the association between obesity, metabolic risks and serum osteocalcin in postmenopausal women.

Methods: We selected 214 postmenopausal women and determined serum osteocalcin, fasting plasma glucose (FPG), fasting insulin, high-sensitivity C-reactive protein (hs-CRP), the homeostasis model assessment of insulin resistance (HOMA–IR), lipid profile, and anthropometric values (BMI, waist-to-hip ratio (WHR), body fat, and visceral fat area (VFA).

Results: After adjustment for age and years since menopause, WHR and VFA were negatively correlated with serum osteocalcin, but BMI did not show a significant correlation. Serum osteocalcin was negatively correlated with fasting insulin and HOMA–IR, but FPG, lipid profile, and blood pressure did not show a significant correlation. Based on multiple regression analysis, age and HOMA–IR were the most important predictors of osteocalcin.

Conclusion: Our study showed that serum osteocalcin has some significance as an indicator of metabolic risk, including abdominal obesity and insulin resistance. Bone as well as adipose tissue may be an active organ that regulates energy metabolism. A larger study will be needed to clarify the potential of osteocalcin as an indicator of cardiovascular disease.